

**SCRIPPS RESEARCH
INSTITUTIONAL BIOSAFETY COMMITTEE
MEETING MINUTES
December 10, 2025**

I. MEETING

The Institutional Biosafety Committee (IBC) of Scripps Research held a meeting via videoconference December 10, 2025, commencing at 2 p.m. Pacific Time. The meeting was held pursuant to notice duly given and a quorum was present.

Committee Members Present		Committee Members Absent	Others Present
Juan Carlos de la Torre	Michael Bobardt	Jim Gohres	Amy Green
Stephen Munday	Smita Chopade	Raphael Park	
Elizabeth Ford	Elizabeth Montano	Cheryl Andreoli	
Roberto Aiolfi	Case McNamara	Steven Robert Head	
Mychelle Fernandez			
Elyse Walk			

I. REVIEW OF PREVIOUS MEETING MINUTES

The Committee voted unanimously to approve the minutes of the November 12, 2025 IBC Meeting.

II. ANNOUNCEMENTS

Phase II of biowaste compliance is complete.

III. BIOSAFETY OFFICER & IBC ADMINISTRATOR'S REPORT

Pathogen Safety Summary Project for Animal Research.

IV. CONFLICT OF INTEREST

Case McNamara will abstain from voting on protocol #s 12-10-25-07 and 12-10-25-08 for the Bakowski lab.

V. REVIEW OF PROTOCOLS

Summary of Discussions: Summaries of each research proposal were thoroughly discussed, including but not limited to: agent characteristics; types of manipulations planned; sources of the nucleic sequences; nature of the nucleic acid sequences; hosts and vectors to be used; whether any attempt will be made to obtain expression of a transgene, and if so, the function of the protein that will be produced. The committee assessed key risks presented by the research and confirmed the appropriate biocontainment level for the conduct proposed.

FULL COMMITTEE REVIEW

AMENDMENT

1. IBC Protocol #: 11-08-23-01B, Wyatt, Richard
Title of Study: Wyatt Lab Protocol
Department: Immunology & Microbiology
Primary Reviewer: Case McNamara
Secondary Reviewer: Beth Ford
NIH Guidelines: III-D-1, III-D-2, III-E-1
Agents: HIV pseudoviruses, lentivirus, Non-human primate primary cells, human cell lines.
Biosafety Level: BSL-2+, ABSL-1
Animal work: ☒ Yes ☐ No

Biosafety Inspection: Inspection of IMM 204C and 205D completed on 8/28/25.
Training: Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

Study Design/Project Description

Door cards need to be updated.

Regulatory Assessment

This work falls under III-D-1 and III-D-2. Those boxes need to be checked.

Risk Assessment

Materials (such as cell lines, tissues) need to be added to this table.

Review outcome: Conditional approval; full approval granted upon completion of the above listed action items.

RENEWALS

1. IBC Protocol #: 12-10-25-01, Racki, Lisa
Title of Study: The Cell Biology of Starvation in Pseudomonas aeruginosa
Department: ISCB
Primary Reviewer: Mychelle Fernandez
Secondary Reviewer: Elyse Walk
NIH Guidelines: III-D-1, III-D-2
Agents: Pseudomonas aeruginosa, human plasma
Biosafety Level: BSL-2
Animal work: ☒ Yes ☐ No
Biosafety Inspection: Inspection of MB 205, 103 completed on 11/19/25.
Training: Pending training.

The following action items were identified as needing to be updated on the protocol:

Location of Study

This section needs to be updated to reflect the use of the Lasker lab and the microscopy core.

Study Design/Project Description

Clarification on the culturing of live cells in the plate reader is needed here.

Risk Assessment

Human plasma needs to be added to the table.

Exposure Control

HBV vaccination needs to be added. Shipping of materials needs clarification.

Review outcome: Conditional approval; full approval granted upon completion of the above listed action items.

2. IBC Protocol #: 12-10-25-03, Erb, Michael
Title of Study: Cell-line models for testing genetic and chemical perturbations
Department: Chemistry
Primary Reviewer: Elyse Walk
Secondary Reviewer: Juan de la Torre

NIH Guidelines:	III-D-1, III-D-2, III-E-1
Agents:	Lentivirus, human cell lines.
Biosafety Level:	BSL-2+
Animal work:	☐ Yes ☒ No
Biosafety Inspection:	Inspection of BCC 526, 515 completed on 11/24/25.
Training:	Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

Location of Study

The BSL-1 location needs to be added, and clarification on MB515 equipment is needed.

Recombinant and Synthetic Nucleic Acids

Vector hosts and cancer cell lines need to be added to the table. Clarification on the source of the large quantity of lentiviral and plasmid expression vectors is needed. Clarification on vector propagation and cloning is also needed.

Infectious Agents

If vector propagation in E. coli occurs, E. coli needs to be added to the table.

Study Design/Project Description

Door cards need to be updated. The generation of large volume of lentivirus needs to be described here. An overall expansion of the project description/experimental design needs to be added here.

Risk Assessment

Human cell lines and E. coli need to be added to the table (if E. coli is being used).

Review outcome: Conditional approval; full approval granted upon completion of the above listed action items.

3. IBC Protocol #: 12-10-25-04, Droujinine, Ilia

Title of Study:	Fecal matter transplantation for murine spondyloarthropathies and mapping of peptide communication between organs and organisms.
Department:	Molecular & Cellular Biology
Primary Reviewer:	Mychelle Fernandez
Secondary Reviewer:	Smita Chopade
NIH Guidelines:	III-D-2, III-D-4
Agents:	Lentivirus, E. coli, Adeno-associated virus, human fecal matter, human cell lines, human serum, human plasma, human skin, human primary cells, human fat, human joints.
Biosafety Level:	BSL-2, ABSL-1
Animal work:	☒ Yes ☐ No
Biosafety Inspection:	Inspection of SR 206, 208A, 202 completed on 11/12/25.
Training:	Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

General Information

The IACUC Protocol link needs to be updated.

Location of Study

The ABSL-2 location needs to be added.

Risk Assessment

Materials need to be added to the table.

Review outcome: Conditional approval; full approval granted upon completion of the above listed action items.

4. IBC Protocol #: 12-10-25-05, Hang, Howard

Title of Study: Immunotherapy Studies

Department: Immunology & Microbiology

Primary Reviewer: Beth Ford

Secondary Reviewer: Case McNamara

NIH Guidelines: III-D-2, III-D-4-b

Agents: Clostridium spp., E. coli, Enterococcus spp., Weissella cibaria, human cell lines.

Biosafety Level: BSL-2, ABSL-2

Animal work: ☒ Yes ☐ No

Biosafety Inspection: Inspection of IMM 115 completed on 1/13/23.

Training: Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

General Information

The AUPs listed need to be updated.

Study Design/Project Description

Door cards need to be updated.

Risk Assessment

Materials need to be added to the table.

Review outcome: Conditional approval; full approval granted upon completion of the above listed action items.

5. IBC Protocol #: 12-10-25-06, Hang, Howard

Title of Study: Infection Studies

Department: Immunology & Microbiology

Primary Reviewer: Roberto Aiolfi

Secondary Reviewer: Smita Chopade

NIH Guidelines: III-D-1, III-D-2, III-D-4

Agents: Salmonella typhimurium, Lactobacillus spp., Lentivirus, E. coli, Staphylococcus spp., Enterococcus spp., human cell lines, non-human primate cell line.

Biosafety Level: BSL-2, ABSL-2

Animal work: ☒ Yes ☐ No

Biosafety Inspection: Inspection of IMM 115 completed on 1/13/23.

Training: Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

Exposure Control

Door cards need updating.

Review outcome: Conditional approval; full approval granted upon completion of the above listed action items.

6. IBC Protocol #: 12-10-25-07, Bakowski, Malina

Title of Study: Drug Discovery for diverse RNA Viruses

Department: Biology- Calibr

Primary Reviewer: Michael Bobardt

Secondary Reviewer: Mychelle Fernandez

NIH Guidelines: III-D-3

Agents: Alphacoronavirus, Betacoronavirus, Cedar Virus, Chikungunya virus, Dengue 1-4, dengue virus type 1-4, Human Metapneumovirus, Human parainfluenza virus, Human Respiratory Syncytial Virus, Human rhinovirus, Japanese encephalitis virus, Poliovirus, Pseudotyped Lentivirus, human cell lines, non-human primate cell lines, Primary human bronchial epithelial cells.

Biosafety Level: BSL-2

Animal work: ☐ Yes ☒ No

Biosafety Inspection: Inspection of Calibr 124, 117E completed on 11/25/25.

Training: Pending training.

The following action items were identified as needing to be updated on the protocol:

General Information

A review of the title and the experiments performed is needed, a title change may be needed.

Infectious Agents

A selection of Yes is needed under the use of vertebrate animals, and the rest of the section must be completed.

Study Design/Project Description

Details on the procedure for growing viruses, the specific volumes of each grown, and the location of those procedures is needed.

Exposure Control

Inactivated polio vaccine (IPV) needs to be added to the list of vaccine offered to personnel.

Review outcome: Not approved; Revisions to be re-reviewed by designated member review.

7. IBC Protocol #: 12-10-25-08, Bakowski, Malina

Title of Study: Drug Discovery for Herpesviruses and other DNA viruses

Department: Biology- Calibr

Primary Reviewer: Roberto Aiolfi

Secondary Reviewer: Michael Bobardt

NIH Guidelines: III-D-1

Agents: Human herpesvirus, human cell lines, non-human primate cell line.

Biosafety Level: BSL-2

Animal work: ☐ Yes ☒ No

Biosafety Inspection: Inspection of Calibr 124, 117E completed on 11/25/25.

Training: Pending training.

Review outcome: Full approval granted.

8. IBC Protocol #: 12-10-25-09, Ward, Andrew

Title of Study: Structural Characterization of pathogenic proteins and the immune response
Department: ISCB
Primary Reviewer: Elyse Walk
Secondary Reviewer: Case McNamara
NIH Guidelines: III-D-1, III-D-2, III-D-7
Agents: Coxsackie virus, E. coli, HIV pseudovirus, influenza virus, lassa virus, Leishmania infantum, lentivirus, norovirus, Plasmodium berghei, retrovirus, zika virus, human blood, human cell lines, human serum, human plasma, non-human primate (serum, plasma, PBMC's).
Biosafety Level: BSL-2
Animal work: ☐ Yes ☒ No
Biosafety Inspection: Inspection of Hazen 122/123 completed on 11/18/25.
Training: Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

General Information

Genetic modifications is needed under the containment assessment.

Location of Study

The location of the CryoEM is needed.

Study Design/Project Description

Door cards need to be updated.

Risk Assessment

Materials need to be added to the table.

Review outcome: Conditional approval; full approval granted upon completion of the above listed action items.

9. IBC Protocol #: 12-10-25-10, Ruf, Wolfram

Title of Study: aPL in COVID-19 patients
Department: Immunology & Microbiology
Primary Reviewer: Smita Chopade
Secondary Reviewer: Michael Bobardt
NIH Guidelines: III-D-1, III-D-2
Agents: Adenovirus, lentivirus, retrovirus, E. coli, human (cell lines, primary cells, plasma, serum).
Biosafety Level: BSL-2, ABSL-1
Animal work: ☒ Yes ☐ No
Biosafety Inspection: Inspection of BCC 515, 519 completed on 11/18/25.
Training: Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

General Information

Links to the IRB and IACUC (AUP) protocols need to be added. Genetic modifications need to be added to the containment assessment.

Infectious Agents

The amount of retrovirus and lentivirus grown in the laboratory needs to be added.

Study Design/Project Description

Door cards need to be updated.

Review outcome: Conditional approval; full approval granted upon completion of the above listed action items.

BIOSAFETY REVIEW

1. IBC Protocol #: **11-10-10-17, Lamia, Katja**

Title of Study: The Role of Cryptochromes and Circadian Clocks in Cellular and Organismal Metabolism.

Department: Molecular & Cellular Biology

NIH Guidelines: III-D-1, III-D-2, III-D-3, III-D-4-b

Agents: Lentivirus, adenovirus, retrovirus, E. coli.

Biosafety Level: BSL-2+, ABSL-2

Animal work: ☒ Yes ☐ No

Training: Training verified and on record.

REVIEW OUTCOME: **Approved.**

2. IBC Protocol #: **08-13-25-01, Chanda, Sumit**

Title of Study: Identify key virus-host interactions for alphaviruses, orthobunyaviruses and orthohantaviruses and development of host-directed broad-spectrum antivirals

Department: Immunology & Microbiology

NIH Guidelines: III-D-1, III-D-2

Agents: Sindbis virus, Eilat virus, Lone Star Virus, La Crosse virus, Oropouche virus, andes orthohantavirus, severe fever with thrombocytopenia syndrome virus, heartland bandavirus, Venezuelan equine encephalitis virus, E. coli, sin nombre virus, black creek canal virus, shamonda virus, schmallerberg virus, human cell lines.

Biosafety Level: BSL-2+, ABSL-3

Animal work: ☒ Yes ☐ No

Training: Training verified and on record.

REVIEW OUTCOME: **Approved.**

VI. ADJOURNMENT

The next scheduled IBC meeting is **Wednesday, January 14, 2026**, via Teams at 2:00 PM. If full committee review protocols are not received by the next deadline date and there are no agenda items for full committee discussion, the meeting will be canceled. Members will be notified via e-mail of meeting cancellations one week before the scheduled meeting.